Table 1.
Baseline characteristics by intervention group
| Characteristic | Liberalized, n=51 | Intensive, n=53 |
|---|---|---|
| Age, yr (SD) | 62.4 (11.1) | 66.3 (13.3) |
| Women, n (%) | 19 (37.3) | 15 (28.3) |
| Primary reason of ESRD, n (%) | ||
| Diabetes | 26 (51.0) | 29 (54.7) |
| Hypertension/ischemic | 7 (13.7) | 10 (18.9) |
| GN | 7 (13.7) | 6 (11.3) |
| PCKD | 4 (7.8) | 2 (3.8) |
| Other | 7 (13.7) | 6 (11.3) |
| Time since commencing hemodialysis, yr (IQR) | 3 (1, 6) | 3 (2, 5) |
| Weekly time on hemodialysis, h (SD) | 11.7 (1.1) | 11.9 (1.6) |
| Urine output >1 cup/d, n (%) | 18 (35.3) | 20 (37.7) |
| Comorbidities, n (%) | ||
| History of coronary artery disease | 15 (29.4) | 18 (34.0) |
| History of diabetes | 29 (56.9) | 35 (66.0) |
| History of stroke | 6 (11.8) | 9 (17.0) |
| Vascular disease | 8 (15.7) | 10 (18.9) |
| Bone-mineral metabolism medication use, n (%) | ||
| Sevelamer | 4 (7.8) | 5 (9.4) |
| Aluminum | 0 (0.0) | 1 (1.9) |
| Alfacalcidol | 17 (33.3) | 23 (43.4) |
| Calcitriol | 9 (17.6) | 14 (26.4) |
| Ergocalciferol | 7 (13.7) | 9 (17.0) |
| Cholecalciferol | 7 (13.7) | 5 (9.4) |
| Cinacalcet | 1 (2.0) | 1 (1.9) |
| History of parathyroidectomy, n (%) | 5 (9.8) | 3 (5.7) |
| Serum phosphate concentration, mg/dl (SD) | 5.52 (0.93) | 5.27 (0.93) |
| mmol/L (SD) | 1.78 (0.30) | 1.70 (0.30) |
| Albumin-adjusted calcium concentration, mg/dl (SD) | 9.30 (0.80) | 9.46 (0.68) |
| mmol/L (SD) | 2.32 (0.20) | 2.36 (0.17) |
| Dialysate ionized calcium concentration mg/dl (IQR) | 5.01 (5.01, 5.01) | 5.01 (5.01, 5.01) |
| mmol/L (IQR) | 1.25 (1.25, 1.25) | 1.25 (1.25, 1.25) |
Continuous data are presented as mean (SD) or median (interquartile range), as appropriate. Categoric data are presented as number (%). Conversion factors: phosphate: 1mmol/L=3.10 mg/dl; calcium: 1mmol/L= 4.01 mg/dl. PCKD, polycystic kidney disease; IQR, interquartile range.